Search Clinical Trials
Withdrawn
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas (External Link)
Earlier, healthy donors gave blood for us to make CD30.CAR-EBVST cells in the laboratory. These cells were grown and frozen and the investigators will select the donor which the investigators …
Baylor Role:
Lead Sponsor
Recruiting
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion (External Link)
This is a phase I/II study of haploidentical HCT (HHCT) with ex vivo TCRαβ+ and CD19+ depletion using the CliniMACS device in patients with hematological malignancies and non-malignant disorders. HHCT …
Baylor Role:
Lead Sponsor
Not Yet Recruiting
Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial (External Link)
An effectiveness-implementation hybrid study is proposed to evaluate the effectiveness of a dual intervention of HPV vaccination and HPV-triage-and-treat to reduce the risk of cervical cancer and to study its …
Enrolling By Invitation
Prospective Evaluation of Self-Testing to Increase Screening (External Link)
Regularly attending for Pap test cervical cancer screening in a clinic is often unfeasible and/or unacceptable to many women. Using mailed self-sampling kits to test for high-risk human papillomavirus (HPV), …
Baylor Role:
Lead Sponsor
Recruiting
Throat and Other HPV-Related Cancers in Men: Identifying Them Early (External Link)
PRIMARY SCIENTIFIC OBJECTIVES: I. To determine the association of antibodies to human papillomavirus type 16 (HPV16) early (E) antigens and circulating HPV16 DNA (cHPVDNA) with oral HPV16 prevalence. II. To …
Baylor Role:
Lead Sponsor
Recruiting
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (External Link)
A healthy donor has given blood to make LMP/BARF1/EBNA-1 MABEL CTLs in the lab. We made the cells by first growing a special type of cells called activated T cells …
Baylor Role:
Lead Sponsor
Active, Not Recruiting
Administration of Donor T Cells With the Caspase-9 Suicide Gene (External Link)
If the patient is doing well after the stem cell transplant, and does not have severe GvHD, s/he will be eligible to receive the special "iCasp9" T cells from Day …
Baylor Role:
Lead Sponsor
Completed
Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) (External Link)
Blood has been previously taken from the patient and the donor to make the cells. To make the special cell line, special blood cells called dendritic cells (DCs)were made first …
Baylor Role:
Lead Sponsor
Completed
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) (External Link)
Patients may be screened for study entry when they have persistent disease despite standard therapy as defined in the inclusion criteria. At that stage a search will be done of …
Baylor Role:
Lead Sponsor
Completed
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) (External Link)
Three different doses of CTL will be evaluated: dose level I: 2 x 10e7/m2; dose level II: 5 x 10e7/m2; dose level III: 1 x 10e8/m2 Day 1 YTH 24/54 …
Baylor Role:
Lead Sponsor